Technology Available for Licensing US Army Medical Research and Materiel Command Recombinant Vaccine Against Botulinum Neurotoxin This invention provides.

Slides:



Advertisements
Similar presentations
Up date on malaria vaccine
Advertisements

Biotechnology Chapter 11.
Antibody Patents in India Pravin Anand 14 th October 2011 Anand and Anand.
病原生物学教研室 Department of pathogenic Biology of Gannan Medical University 医学微生物学 Medical Microbiology 张文平.
Botulinum toxin By: james and alan. The most poisonous substance known to man Produced by the common bacteria Clostridium botulinum Cause of Botulism.
Death Death results from loss of diaphragmatic and accessory respiratory muscle function  insufficient tidal volume, dyspnea or ventilary failure Death.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
About Swine Flu Dr.Kedar Karki. What is Swine Influenza? Swine Influenza (swine flu) is a respiratory disease of pigs caused by type A influenza virus.
General Microbiology (Micr300)
LOCALIZATION OF A MOLECULE - placing in space and or time. -Answering where and/when.
1. Within a few years, more than half of newly approved medicines will be biopharmaceuticals. To ensure safety and efficacy, the FDA created a daunting.
Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.
u Proteins that recognize and bind to a particular antigen with very high specificity. u Made in response to exposure to the antigen. u Each antibody.
Types of vaccines 1 - First generation vaccines are whole-organism vaccines - either live and weakened, or killed forms. [1] Live, attenuated vaccines,
Specific prophylaxis and treatment of infectious diseases Medical biology, microbiology, virology, immunology department By as. E.V. Pokryshko.
Active and passive immunization Immunity to infectious microorganisms: Immunity to infectious microorganisms: 1- Active immunization *** natural processes.
Immunoprevention. Definition By using immunological agents to construct, improve or inhibit immune response, people can prevent some diseases.
Outline  History  Uses  Toxin and Toxic Effects  Mechanisms of Action  Summary  Conclusion  References.
Rotaviruses Kaemwich Jantama Chemical Engineering.
Clostridium botulinum Prepared by: Shiekha AL-Aujan.
“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.
Technology Available for Licensing US Army Medical Research and Materiel Command A Pharmaceutical Composition Containing pGLU- GLU-PRO-NH 2 and Methods.
CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS Dr.G.Hima Bindu MD; PG dip. diabetology Asst.Professor Dept. of Pharmacology Rajiv Gandhi Institute.
Immunity Immunity is a biological term that describes a state of having sufficient biological defenses to avoid infection, disease, or other unwanted biological.
Forensic Science: Fundamentals & Investigations, Chapter 9 1 Chapter 9 Drug Identification and Toxicology By the end of this chapter you will be able to:
Jessica M. Boehmler* and Jeffrey P. Thompson Department of Biological Sciences, York College of Pennsylvania ABSTRACT Botulinum neurotoxin (botox), found.
Specific prophylaxis and treatment of infectious diseases Medical biology, microbiology, virology, immunology department.
ANTIBODIES def - protein molecules that combine specifically with antigens. Proteins with antibody activity are known as immunoglobins.
ACTIVE AND PASSIVE IMMUNIZATION. Two types of immunization Active immunization - natural infection - vaccination, that provides people with an immunological.
Introduction to Biotechnology Chapter 13. What is biotechnology? “ Any technique that uses living organisms or their products to make or modify a product,
Lecture 1: Immunogenetics Dr ; Kwanama
Biotechnology Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Making Vaccines. Effective Vaccines Have low levels of side effects or toxicity. Protect against exposure to natural, or wild forms of the pathogen. Should.
Rational Strategies Interventions of choiceInterventions of choice Economic, social and other non-medical countermeasures Interventions of last resortInterventions.
Protection against Disease
ANTIBODIES Agents of Immunity - A Guide for Teachers - Prepared by Johanna Mancini for Immunology Montreal August 2008.
Viral vaccines  .
Virus vaccines LECTURE 18: Viro100: Virology 3 Credit hours NUST Centre of Virology & Immunology Waqas Nasir Chaudhry.
Medical Bacteriology MBIO 460 Lecture 12 Dr. Turki Dawoud 2 nd Semester 1436/1437 H.
Vaccines.
Page 1 Yeast Expression System — Creative BioMart.
Biologic Medicines.
Vaccines.
BOTOX – By Dutchess Neurology
Molecular Therapy - Methods & Clinical Development
Tetanus.
Immune system-Acquired/Adaptive immunity
DISCUSSION AND CONCLUSION
Antibodies (Immunoglobulin)
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
The Differentiation of Vertebrate Immune Cells
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
Immunology.
Immunization/Vaccination
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
Introduction/Terminology
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
US Army Medical Research and Materiel Command
Presentation transcript:

Technology Available for Licensing US Army Medical Research and Materiel Command Recombinant Vaccine Against Botulinum Neurotoxin This invention provides for the expression of synthetic genes that encode polypeptides containing protective epitopes of botulinum neurotoxins (BoNTs). When produced by Clostridium botulinum, BoNTs cause botulism by blocking the transmission of neuromuscular stimuli. The invention also includes a vaccine against botulism using the expressed polypeptides. BoNTs are among the most toxic substances known, and only a few molecules are needed to abolish nerve cell activity, which can lead to respiratory failure and death. Humans are naturally affected by BoNTs via food poisoning, infant botulism, and wound botulism. Botulism poisoning could also occur during biological warfare or accidental laboratory exposure. Seven different antigenically distinct serotypes (A - G) of BoNTs have been characterized. Although polyclonal antibodies derived for a specific serotype can neutralize its toxic effects, they cannot cross-neutralize another serotype. The vaccine currently used against botulism is a pentavalent toxoid (i.e., serotypes A, B, C1, D and E). However, the vaccine is not only dangerous and expensive to produce, but also contains formalin, which causes reactogenic effects in recipients. The vaccine is incomplete as it only protects against serotypes A – E and requires four inoculations over 12 months. A more efficacious vaccine against all seven BoNT serotypes that will protect humans against natural, laboratory work-related, and biological warfare-related exposures is needed. A new generation recombinant vaccine could alleviate many of the problems associated with the current vaccine. Culturing of large quantities of highly toxic C. botulinum and a dedicated current good manufacturing practices (cGMP) facility would not be needed. Additionally, the new vaccine would be purer, less reactogenic, more fully characterized, and cheaper to produce. Licensing Opportunities Patent licenses are available to companies with commercial interests Features and advantages: Expresses synthetic gene products encoding C-terminal ends of heavy chain fragments of botulinum neurotoxin Recombinant-BoNT protein fragment and plasmid products are completely nontoxic Large quantities have been expressed in the Pichia pastoris expression system Serotype B synthetic gene fragment protected mice, guinea pigs, and non-human primates Serotypes A, B, C, E, and F synthetic gene fragments elicit protection in mice Immunogenicity studies for serotypes D and G are in progress Patent Status Point of Contact Director, Office of Research and Technology Applications USAMRMC, MCMR-ZA-J 504 Scott St., Frederick, MD Voice: /2065/7219 Fax: KEYWORDS: Vaccine; botulinum neurotoxin; fragment C; Pichia pastoris Patent Application No.: Date Published: January 9, 2003 Available from: Docket No.: RIID 99-29